13F Holdings
中文EN

FRNM Freenome, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2017526 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY59.4%
TTM EPS YoY73.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-23.7%
ROA-17.7%
ROIC (approx.)29.0%
Asset turnover—

Leverage & solvency

Liabilities / assets34.4%
Debt / equity0.00x
Current ratio12.73x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31
Income statement
Revenue—
SG&A expense$2.98M
Operating income-$2.98M
Net income$837,468
EPS (diluted)—
Balance sheet
Cash & equivalents$78.56M
Receivables$1.31M
Inventory$0
Current assets$226.49M
PP&E, net$155.78M
Goodwill$10.51M
Intangibles$3.30M
Total assets$507.05M
Current liabilities$40.53M
Total liabilities$406.61M
Shareholders' equity$100.44M
Shares outstanding67.94M
Cash flow statement
Operating cash flow-$864,653
Investing cash flow$600,000
Financing cash flow$0

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.